[Living donor liver transplantation in a patient with HIV].
Highly active anti-retroviral therapy(HAART) for human immunodeficiency virus(HIV) has delayed the disease progression. The advances prompted us to undertake liver transplantation in a 41-year-old man with hemophilia B, HIV infection, and hepatitis C(HCV) end-stage liver disease. The donor was the patient's elderly brother. His right liver was implanted by the standard method. Two months after the operation, interferon alfa and ribavirin were administered for HCV infection. HCV was eradicated two weeks after the treatment. The HIV viral load is persistently negative and HAART has not been started so far. Utilizing a organ from living relatives should be one of the options to resolve the concern around the utilization of a scarce public source from cadavers for patients who may not have an equivalent survival to HIV negative patients.
Sugawara
Yasuhiko
Y
Artificial Organ & Transplantation Division, Department of Surgery, Postgraduate School of Medicine, University of Tokyo.
Makuuchi
Masatoshi
M
Morisawa
Yuuji
Y
Kimura
Satoshi
S
Tachikawa
Natsuo
N
Oka
Shinichi
S
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006679:HIV Seropositivity / Q000150:complications* / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D002836:Hemophilia B / Q000150:complications; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000628:therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D016031:Liver Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin